Sarissa Capital's Alex Denner: Biotech is fairly valued
Share

Sarissa Capital's Alex Denner: Biotech is fairly valued

CNBC's Meg Tirrell speaks with Alex Denner, Sarissa Capital, about the valuation of the biotech sector.
04:49
Wed, Mar 28 201812:28 PM EDT